Search: onr:"swepub:oai:lup.lub.lu.se:5d8bf9fc-671d-4250-a550-09d655f2be1d" >
Impact of prior the...
-
Mateos, María-VictoriaUniversity Hospital of Salamanca
(author)
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
- Article/chapterEnglish2017
Publisher, publication year, extent ...
-
2017-07-27
-
Ferrata Storti Foundation (Haematologica),2017
-
9 s.
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:5d8bf9fc-671d-4250-a550-09d655f2be1d
-
https://lup.lub.lu.se/record/5d8bf9fc-671d-4250-a550-09d655f2be1dURI
-
https://doi.org/10.3324/haematol.2017.170118DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Prior treatment exposure in patients with relapsed/refractory multiple myeloma may affect outcomes with subsequent therapies. We analyzed efficacy and safety according to prior treatment in the phase 3 TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) versus placebo-Rd. Patients with relapsed/refractory multiple myeloma received ixazomib-Rd or placebo-Rd. Efficacy and safety were evaluated in subgroups defined according to type (proteasome inhibitor [PI] and immunomodulatory drug) and number (1 vs. 2 or 3) of prior therapies received. Of 722 patients, 503 (70%) had received a prior PI, and 397 (55%) prior lenalidomide/thalidomide; 425 patients had received 1 prior therapy, and 297 received 2 or 3 prior therapies. At a median follow up of ~15 months, PFS was prolonged with ixazomib-Rd vs. placebo-Rd regardless of type of prior therapy received; HR 0.739 and 0.749 in PI-exposed and -naïve patients, HR 0.744 and 0.700 in immunomodulatory-drug-exposed and -naïve patients, respectively. PFS benefit with ixazomib-Rd vs. placebo-Rd appeared greater in patients with 2 or 3 prior therapies (HR 0.58) and in those with 1 prior therapy without prior transplant (HR 0.60) versus those with 1 prior therapy and transplant (HR 1.23). Across all subgroups, toxicity was consistent with that seen in the intent-to-treat population. In patients with relapsed/refractory multiple myeloma, ixazomib-Rd was associated with a consistent clinical benefit vs. placebo-Rd regardless of prior treatment with bortezomib or immunomodulatory drugs. Patients with 2 or 3 prior therapies, or 1 prior therapy without transplant seemed to have greater benefit than patients with 1 prior therapy and transplant. TOURMALINE-MM1 registered at clinicaltrials.gov identifier: 01564537.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Masszi, TamasSemmelweis University
(author)
-
Grzasko, NorbertMedical University of Lublin
(author)
-
Hansson, MarkusLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital(Swepub:lu)hema-mha
(author)
-
Sandhu, IrwindeepUniversity of Alberta
(author)
-
Pour, LudekMasaryk University
(author)
-
Viterbo, LuísaInstituto Português de Oncologia do Porto Francisco Gentil (IPO)
(author)
-
Jackson, Sharon RMiddlemore Hospital, Auckland
(author)
-
Stoppa, Anne-MarieInstitut Paoli-Calmettes
(author)
-
Gimsing, PeterCopenhagen University Hospital
(author)
-
Hamadani, MehdiMedical College of Wisconsin
(author)
-
Borsaru, GabrielaColțea Hospital
(author)
-
Berg, DeborahTakeda Oncology Inc.
(author)
-
Lin, JianchangTakeda Oncology Inc.
(author)
-
Di Bacco, AlessandraTakeda Oncology Inc.
(author)
-
van de Velde, HelgiTakeda Oncology Inc.
(author)
-
Richardson, Paul GDana-Farber Cancer Institute
(author)
-
Moreau, PhilippeNantes University Hospital
(author)
-
University Hospital of SalamancaSemmelweis University
(creator_code:org_t)
Related titles
-
In:Haematologica: Ferrata Storti Foundation (Haematologica)102:10, s. 1767-17751592-87210390-6078
Internet link
Find in a library
To the university's database
- By the author/editor
-
Mateos, María-Vi ...
-
Masszi, Tamas
-
Grzasko, Norbert
-
Hansson, Markus
-
Sandhu, Irwindee ...
-
Pour, Ludek
-
show more...
-
Viterbo, Luísa
-
Jackson, Sharon ...
-
Stoppa, Anne-Mar ...
-
Gimsing, Peter
-
Hamadani, Mehdi
-
Borsaru, Gabriel ...
-
Berg, Deborah
-
Lin, Jianchang
-
Di Bacco, Alessa ...
-
van de Velde, He ...
-
Richardson, Paul ...
-
Moreau, Philippe
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Haematologica
- By the university
-
Lund University